MAAT PHARMA Aktie

 

The Company received an upfront payment of €10.5 million in July 2025 after the signature of an exclusive license and distribution agreement with Clinigen. Subject to approval and grant of a Marketing Authorization by the European Medicines Agency, it has the potential to facilitate patient access of Xervyteg®(MaaT013) across Europe. The Company received €3.5 million in October 2025 from the successful drawdown of Tranche A of the €37.5 million, 4-tranche financing from the European Investment Bank (EIB). As of September 30, 2025, cash and cash equivalents were €22.4 million; cash runway confirmed to the end of February 2026. Revenues of €3.4 million at the end of Q3 2025, a 45% increase year-over-year1. LYON, France--(BUSINESS WIRE)--$MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through im...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant clinical improvement over currently available therapies. Marketing Authorization application of Xervyteg® (MaaT013) in aGvHD submitted to the European Medicines Agency (EMA) in June 2025. Signature of a license and commercial agreement with Clinigen to facilitate patient access across Europe. €10.5 million upfront payment received and €18 million additional payments depending on the achievement of pre-specified regulatory and sales milestones. The Company will also be eligible to receive royalty payments on both EAP treatments and net commercial sales of a percentage in the mid-thirties and regular cash flow as per the supply agreement of Xervyteg®. Signature of a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The ...

Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg® currently under review for potential approval by the EMA and MaaT033 currently in Phase 2b clinical evaluation Funding is part of the European Investment Bank (EIB)'s strategy to support biotech companies with cutting-edge expertise in therapeutic areas such as hemato-oncology Structured Debt financing from the EIB is another stepping stone in MaaT Pharma's multi-sourcing financing strategy LYON, France--(BUSINESS WIRE)--$MAAT #EIB--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hema...

Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers)LYON, France--(BUSINESS WIRE)--$MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on June 30, 2025. Listing place: Euronext Paris ISIN code: FR0012634822 Website: www.maatpharma.com Date Total number of shares comprising the share capital Total number of theoretical voting rights (1) Total number of effective voting rights (2) 06/30/25 16,135,971 16,135,971 16,135,971 (1) In accordance with Article 22...

LYON, France--(BUSINESS WIRE)--$MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today presents the results of its Annual and Extraordinary General Meeting held on Friday, June 20, 2025 at 9:30 am CET at the Company's office and broadcasted live (replay available here). The quorum reached by the shareholders present, representing, or voting remotely, was above 73% of voting shares. Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 99% (with the exception of the 29th and 34th resolutions approved by nearly 69% of voters). The following resolutions were approved: Approval of the financial statements for fiscal year 2024; The compensation policy for corporate officers (Chairman, Chief Executive Officer and Dir...

Marketing Authorization application of Xervyteg® (MaaT013) in acute graft-versus-host-disease submitted to the European Medicines Agency (EMA) in June 2025 MAA could be expected in H2 2026 allowing, if approved, for commercialization of Xervyteg® in Europe As part of a strategic focus on Xervyteg®'s registration activities in Europe, the Phase 3 dedicated trial launch in the U.S is now expected in 2026 The Company's General Meeting will take place on June 20, 2025, at 9.30am CET at the Company's headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live LYON, France--(BUSINESS WIRE)--$MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provides a business update and highlights its key milestones expected for the second half of ...

LYON, France--(BUSINESS WIRE)--$MAAT #GeneralMeeting--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, informs its shareholders that the Annual General Meeting (ordinary and extraordinary) will be held on June 20, 2025, at 9:30am CET at the Company's headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live. A presentation by the management team on recent developments and perspectives will take place from 9:00 to 9:30 a.m. CET, prior to the General Meeting. This will be followed by a Q&A session during which shareholders will have the opportunity to ask questions. The notice of meeting, serving as convening notice is published in the Bulletin des annonces légales obligatoires on Wednesday, 14 May 2025 (https://www.journal-officiel.gouv.fr/pages/ba...

Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant clinical improvement over currently available therapies; Positive final DSMB review confirming remarkable efficacy results and a positive benefit/risk profile. Marketing Authorization Application (MAA) in Europe for MaaT013 on track for EMA submission in June 2025. Second safety assessment completed by DSMB with positive outcome and first milestone of unblinded interim safety review reached for Phase 2b trial of MaaT033 for patients receiving allo-HSCT; both reviews concluded positively with the recommendation that the trial proceed without modification. EAP Revenues of €1.1 million in Q1 2025, a 37,5% increase over Q1 2024. As of March 31, 2025, cash and cash equivalents were €24.4 million, taking into account the capital increase of March 2025 o...

LYON, France--(BUSINESS WIRE)--$MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 11, 2025, under number D.25-0249. The 2024 Universal Registration Document includes the following documents: The annual financial report for the fiscal year ended December 31, 2024, including the Board of Directors' Corporate Governance Report; The auditors' reports and information related to their fees, Information on the Company's share buyback program; The 2024 Universal Registration Document is available on the Company's website, in the 'Investors' section under "Regulated Information", as well as ...

LYON, France--(BUSINESS WIRE)--$MAAT #Analysts--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announces the initiation of coverage of its stock by H.C. Wainwright & Co. With a research report named “In With the Gut and Out With the Bad in GvHD; Initiating at Buy With a €21 PT”, H.C. Wainwright & Co initiated coverage of MaaT Pharma on April 4th, 2025 with a Buy recommendation and a Target Price of €21. H.C. Wainwright & Co, a leading full-service U.S. investment bank, provides corporate finance, strategic advisory, and related services to public and private companies across a wide range of sectors and geographies. Their initiation of coverage underscores the strong global potential of MaaT Pharma and its therapies and marks an important step toward expanding its presence in the U.S...

Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant improvement over currently available therapies; Positive final DSMB review confirming remarkable efficacy results and a positive benefit/risk profile. Marketing Authorization Application (MAA) in Europe for MaaT013 on track for EMA submission in June 2025. Initiation of Expanded Access for MaaT013 in aGvHD in the U.S. EAP Revenues of €3.2 million in 2024, a 44% increase over 2023, and the highest revenues generated from the EAP to date. As of December 31, 2024, cash and cash equivalents were €20.2 million. Capital Increase of €13 million supported by historical shareholders to advance towards its next significant operational and financing milestones, extending its cash runway into October 2025. LYON, France--(BUSINESS WIRE)--$MAAT...